MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]
MoonLake Immunotherapeutics (MLTX) had its price target raised by HC Wainwright from $32.00 to $40.00. They now have a "buy" rating on the stock.
MoonLake Immunotherapeutics (MLTX) was upgraded by Zacks Research from "strong sell" to "hold".
MoonLake Immunotherapeutics (NASDAQ:MLTX) had its price target raised by analysts at BTIG Research from $24.00 to $30.00. They now have a "buy" rating on the stock.